Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference on March 9-10, 2021. CEO Ryan Spencer will lead the presentation, which will be available on demand starting at 7:00 a.m. E.T. on March 9, accessible via the Investors section of the company’s website. Dynavax specializes in developing vaccines, having commercialized HEPLISAV-B®, a hepatitis B vaccine, and is advancing CpG 1018 as a vaccine adjuvant for various collaborations.

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference being held March 9-10, 2021.

The on demand presentation will be available, beginning Tuesday, March 9, 2021 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-2021-global-life-sciences-conference-301237827.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference?

Dynavax is scheduled to present on March 9-10, 2021.

Who will represent Dynavax during the conference?

CEO Ryan Spencer will represent Dynavax at the conference.

When will the on-demand presentation from Dynavax be available?

The on-demand presentation will be available starting March 9, 2021, at 7:00 a.m. E.T.

Where can I access Dynavax's conference presentation?

The presentation can be accessed through the 'Events & Presentations' page on Dynavax's website.

What is Dynavax's main product?

Dynavax's first commercial product is HEPLISAV-B®, a hepatitis B vaccine.

What are Dynavax's research collaborations focused on?

Dynavax's collaborations are focused on adjuvanted vaccines for COVID-19, pertussis, and universal influenza.